Xeljanz/Xeljanz XR Lawsuits
Xeljanz and Xeljanz XR (tofacitinib) are used to treat rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis. We previously alerted readers to a warning by the U.S. Food and Drug Administration (FDA) in February 2019 about an increased risk of blood clots and death in patients who are taking Xeljanz for the treatment of RA. The FDA issued another alert in February 2021 to warn patients that the use of Xeljanz is associated with serious cardiovascular problems and cancer based on preliminary results from a clinical safety trial.
Related: FDA Warns of New Dangers Associated with JAK Inhibitors
Xeljanz Lawyers are Ready to Help
Contact our Xeljanz Lawyers to review whether you or a family member may be entitled to financial compensation. Levy Konigsberg LLP is currently accepting Xeljanz cases in all 50 states.
If you or a loved one has suffered one or more of these complications, you may be entitled to a cash award and compensation for medical expenses. For a free confidential consultation with Xeljanz Lawyers at our law firm, please call 1-800-988-8005 or submit an email inquiry above.
What is Xeljanz?
Rheumatoid arthritis is an autoimmune disorder that causes chronic inflammation in the joints. Xeljanz is an oral medication that treats moderate to severe forms of RA by reducing pain and tenderness in the joints. Xeljanz has also been prescribed to treat psoriatic arthritis and ulcerative colitis.
What is Happening with Xeljanz?
The FDA alert in February 2021 warns patients that Xeljanz and Xeljanz XR may be linked to a higher risk of serious heart-related issues and cancers as compared to other medications prescribed for the treatment of RA. These findings emerged as the result of a clinical trial that the FDA ordered to evaluate the safety of Xeljanz.
The initial review of Xeljanz/Xeljanz XR by the FDA in February 2019 prompted a warning after the agency discovered an increased risk of blood clots and death in patients receiving a dose of 10 mg twice daily of Xeljanz. The results of the completed clinical trial confirm that serious cardiovascular events and cancers are associated with the double dose treatment of Xeljanz in patients who have RA. The risk of these adverse events was higher when compared to alternative treatments for RA, namely tumor necrosis factor inhibitors (TNF), commonly known by the drug name Humira. The FDA has stated that further results from the clinical trial are pending and it intends to work with Pfizer to provide more information regarding the risks of the medication.
Xeljanz Side Effects and Complications
Serious side effects of Xeljanz, Xeljanz XR include:
- Blood clots, including pulmonary embolism and deep vein thrombosis;
- Cardiovascular conditions, such as heart attack and stroke;
- Cancer; and
- Death.
Xeljanz Lawyers are Ready to Help
Contact our Xeljanz Lawyers to review whether you or a family member may be entitled to financial compensation. Levy Konigsberg LLP is currently accepting Xeljanz cases in all 50 states.
If you or a loved one has suffered one or more of these complications, you may be entitled to a cash award and compensation for medical expenses. For a free confidential consultation with Xeljanz Lawyers at our law firm, please call 1-800-988-8005 or submit an email inquiry above.
